Kevin Charles Gorman, Chief Executive Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 58,088 shares at $105.68 ($6.0M) on 2023-02-06, disclosed to the SEC on 2023-02-08.
Seasonal sale ($6.0M) by Chief Executive Officer — this insider has traded NBIX in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $105.68 | 3,040 | $321K | 5.4% |
| 2 | $105.68 | 3,040 | $321K | 5.4% |
| 3 | $102.30 | 3,248 | $332K | 5.6% |
| 4 | $102.30 | 3,248 | $332K | 5.6% |
| 5 | $102.43 | 20,482 | $2.1M | 35.1% |
| 6 | $102.43 | 20,482 |
| $2.1M |
| 35.1% |
| 7 | $104.30 | 2,274 | $237K | 4.0% |
| 8 | $104.30 | 2,274 | $237K | 4.0% |
| Total | $102.90 avg | 58,088 | $6.0M | 100% |
| Filing → |
| NBIX | SELL | 2025-08-11 | $26.9M | — | Filing → |
| XNCR | SELL | 2025-06-16 | $29K | — | Filing → |
| NBIX | SELL | 2025-05-29 | $2.3M | — | Filing → |